FORCE Blog

This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.

| More

Posts Tagged ‘ovarian cancer treatment’

April 12, 2018

PARP Inhibitors and Hereditary Cancer: What’s New?

by Sue Friedman PARP inhibitors are drugs designed specifically to treat cancers in people with certain inherited mutations, including BRCA1 and BRCA2, among others. These drugs block an enzyme – known as PARP – used by cells to repair damage to their DNA. Although these agents seem to be most effective in people with mutations—not just … + read more

March 28, 2017

SOLO3: A Clinical Trial Comparing the PARP Inhibitor, Olaparib to Standard Chemotherapy for Platinum-Sensitive Relapsed Ovarian Cancer

by Jordan Dietrich  SOLO3 SOLO3 is an exciting phase III ovarian cancer clinical trial that studies the effectiveness and safety of the PARP inhibitor Olaparib (Lynparza) compared to single-agent standard chemotherapy in women with platinum-sensitive relapsed ovarian cancer with germline BRCA1/2 mutations. The trial is designed to confirm the benefit of Olaparib in this subset of … + read more

January 31, 2017

MEDIOLA: A Clinical Trial Combining a PARP Inhibitor with an Immunotherapy Drug

By Ding Wang, MD and Catherine Jenovai Immune system and cancer Every day our bodies are exposed to various injuries that may damage our cells. The damaged cells with certain types of genetic defects are tagged as abnormal and removed by our immune system. If something goes wrong and the cells are not removed by … + read more

May 10, 2016

Experience with Oncology Clinical Trial Participation and Impact on Future Trial Design and Conduct

Note: Last year, TESARO, a pharmaceutical company developing a new PARP inhibitor for treatment of ovarian cancer and metastatic breast cancer, asked FORCE to help recruit previous clinical trial participants to join focus groups across the U.S. TESARO wanted to understand the patient experience to build clinical trials that are more responsive to patient needs. We … + read more

Connect with others.

Call our Helpline

Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.

Join a Local Group

FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.

FORCE:Facing Our Risk of Cancer Empowered